Status:
UNKNOWN
Analysis of Next Generation PET and Liquid Biopsy to Monitor mCRPC Treated With Abiraterone: ANGELA Trial
Lead Sponsor:
Fudan University
Conditions:
Prostate Cancer
Castration-resistant Prostate Cancer
Eligibility:
MALE
18-85 years
Brief Summary
By incorporating dual-tracer PET/CT (PSMA and FDG) and ctDNA, we aimed to evaluate lesion heterogeneity and genomic change of mCRPC patients receiving novel hormonal therapy. The relationship between ...
Eligibility Criteria
Inclusion
- Diagnosed as mCRPC according to EAU-ESTRO-SIOG 2016 and PSA \> 10ng/ml;
- No previous treatment with novel hormonal therapy;
- ECOG 0-2;
- Normal organ function, WBC \>= 3000/mm3 or Neutrophil \>= 1500/mm3;
- Aged 18 to 85 years old when issuing written informed consent;
- Life expectancy \> 12 months.
- Consent and able to carry out follow-up visit and cooperate with all other study procedures.
Exclusion
- Severe disease or other medical conditions suggesting a high risk of death within 1 year, which may interfere with follow-up. Decided by investigator;
- Diagnosed with any other malignant tumor within 3 years before enrollment;
- Unable to provide necessary follow-up information;
- Other conditions that are judged as ineligible by the investigator.
Key Trial Info
Start Date :
July 15 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 15 2022
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT05188911
Start Date
July 15 2020
End Date
July 15 2022
Last Update
January 12 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China, 200000